Gemini Therapeutics (GMTX) Competitors $89.94 +15.58 (+20.95%) As of 10/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock GMTX vs. RDY, VTRS, ROIV, BBIO, QGEN, MRNA, ELAN, VRNA, RVMD, and ABVXShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Qiagen (QGEN), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Its Competitors Dr. Reddy's Laboratories Viatris Roivant Sciences BridgeBio Pharma Qiagen Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Abivax Gemini Therapeutics (NASDAQ:GMTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Do analysts prefer GMTX or RDY? Dr. Reddy's Laboratories has a consensus price target of $16.95, suggesting a potential upside of 17.42%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Dr. Reddy's Laboratories 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has more risk and volatility, GMTX or RDY? Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Does the media prefer GMTX or RDY? In the previous week, Dr. Reddy's Laboratories had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 0 mentions for Gemini Therapeutics. Dr. Reddy's Laboratories' average media sentiment score of 1.28 beat Gemini Therapeutics' score of 0.67 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Overall Sentiment Gemini Therapeutics Positive Dr. Reddy's Laboratories Positive Which has higher valuation & earnings, GMTX or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-89.94Dr. Reddy's Laboratories$334.26B0.04$663M$0.6621.87 Is GMTX or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to Gemini Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Dr. Reddy's Laboratories 16.99%17.25%11.63% Do institutionals and insiders hold more shares of GMTX or RDY? 75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryDr. Reddy's Laboratories beats Gemini Therapeutics on 14 of the 16 factors compared between the two stocks. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.90B$1.03B$6.09B$10.49BDividend YieldN/A4.84%5.73%4.80%P/E Ratio-89.941.3285.3827.13Price / SalesN/A147.79519.70179.85Price / CashN/A17.6337.2361.22Price / Book31.128.0712.236.52Net Income-$71.87M-$7.36M$3.33B$276.93M7 Day Performance28.67%-1.70%1.18%1.94%1 Month Performance47.36%27.11%6.15%2.19%1 Year Performance78.13%-12.95%60.00%35.00% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$89.94+21.0%N/A+54.9%$3.90BN/A-89.9430Gap UpHigh Trading VolumeRDYDr. Reddy's Laboratories3.0633 of 5 stars$13.95-2.9%$16.95+21.5%-9.6%$11.64B$3.81B21.1327,811Positive NewsVTRSViatris3.0514 of 5 stars$9.93+0.7%$10.40+4.7%-13.2%$11.58B$14.74B-3.4232,000News CoverageAnalyst ForecastROIVRoivant Sciences2.9452 of 5 stars$16.40+1.2%$19.94+21.6%+44.9%$11.20B$29.05M-23.43860Insider TradeBBIOBridgeBio Pharma4.4915 of 5 stars$56.50+1.0%$63.94+13.2%+109.7%$10.80B$221.90M-13.81400Positive NewsAnalyst RevisionQGENQiagen4.1173 of 5 stars$47.49+0.6%$49.40+4.0%+16.3%$10.56B$1.98B28.065,765News CoveragePositive NewsMRNAModerna4.2557 of 5 stars$26.25-1.8%$41.81+59.3%-52.6%$10.25B$3.24B-3.495,800Trending NewsOptions VolumeAnalyst RevisionGap DownELANElanco Animal Health2.586 of 5 stars$20.25+1.0%$19.14-5.4%+66.9%$10.06B$4.44B23.549,000Analyst RevisionVRNAVerona Pharma PLC American Depositary Share1.5418 of 5 stars$106.91flat$109.00+2.0%N/A$9.21B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.3971 of 5 stars$47.50-2.6%$74.64+57.1%+8.2%$8.88B$11.58M-10.56250News CoverageAnalyst ForecastInsider TradeABVXAbivax3.5024 of 5 stars$97.82+2.3%$114.25+16.8%+795.9%$7.61BN/A0.0061Short Interest ↓ Related Companies and Tools Related Companies Dr. Reddy's Laboratories Alternatives Viatris Alternatives Roivant Sciences Alternatives BridgeBio Pharma Alternatives Qiagen Alternatives Moderna Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Abivax Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GMTX) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GMTX Stock Alerts